Chronic Kidney Disease-mineral Bone Disorder and Active Vitamin D Analogs for Treating Severe Hyperparathyroidism in Children Receiving Chronic Peritoneal Dialysis = 소아복막투석환자에서 CKD-MBD와 중증 부갑상샘 기능항진증에서 비타민 D 치료

다국어 초록 (Multilingual Abstract)

Purpose: The aims of this study were to assess the clinical and laboratory profiles of chronic kidney disease-mineral bone disorder (CKD-MBD) and to assess the effects of treatment of active vitamin D analogs on severe hyperparathyroidism (SHPT) in pediatric patients on chronic peritoneal dialysis. Methods: This is a retrospective study included 53 patients who had been undergoing dialysis for more than 1 year, between January 2003 and December 2012. Results: Even after treatment with phosphate binders and active vitamin D analogs, the $mean{\pm}standard$ deviation of the percentage of time during peritoneal dialysis that the patients' serum concentrations of phosphorus, corrected total calcium, and parathyroid hormone (PTH) fell within the Kidney Disease Outcomes Quality Initiative recommended ranges was $25.06{\pm}17.47%$, $53.30{\pm}23.03%$, and $11.52{\pm}9.51%$, respectively. Clinical symptoms or radiological signs of CKD-MBD were observed in 10 patients (18.9%). There were significant differences in percentage of time that the serum intact PTH concentration was outside of the recommended range between patients with and without symptoms or signs of CKD-MBD (below recommended range, $11.74{\pm}7.37%$ vs. $40.77{\pm}25.39%$, P <0.001; above the recommended range, $63.79{\pm}27.86%$ vs. $37.09{\pm}27.76%$, P =0.022). Of the 25 patients with SHPT, high-dose alfacalcidol treatment was required in 13 patients that controlled SHPT in 7 of these patients, without marked complications. Conclusion: Despite our efforts to manage CKD-MBD, patients' met the recommended ranges from relevant guidelines at a low frequency. The treatment of high-dose active vitamin D analogs was required in about half of the patients with SHPT and effective in about half of them.

참고문헌 (Reference)

1 Duranton F, "Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis" 37 : 239-248, 2013

2 Gonzalez EA, "Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study" 24 : 503-510, 2004

3 Borzych D, "The bone and mineral disorder of children undergoing chronic peritoneal dialysis" 78 : 1295-1304, 2010

4 Messa P, "The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism" 3 : 36-45, 2008

5 Groothoff JW, "Severe bone disease and low bone mineral density after juvenile renal failure" 63 : 266-275, 2003

6 Palmer SC, "Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis" 305 : 1119-1127, 2011

7 Shinaberger CS, "Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients" 3 : 1769-1776, 2008

8 Klaus G, "Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines" 21 : 151-159, 2006

9 Cho HY, "Prevalence of 25(OH) vitamin D insufficiency and deficiency in pediatric patients on chronic dialysis" 33 : 398-404, 2013

10 Naves-Diaz M, "Oral active vitamin D is associated with improved survival in hemodialysis patients" 74 : 1070-1078, 2008

11 Tentori F, "Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)" 52 : 519-530, 2008

12 Shroff RC, "Mineral metabolism and vascular damage in children on dialysis" 18 : 2996-3003, 2007

13 "KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)" S1-S130, 2009

14 "K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease" S1-S122, 2005

15 Frazao JM, "Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism" 36 : 550-561, 2000

16 Tangri N, "Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry" 57 : 415-421, 2011

17 Goodman WG, "Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy" 46 : 1160-1166, 1994

18 Fouque D, "Control of mineral metabolism and bone disease in haemodialysis patients: which optimal targets?" 28 : 360-367, 2013

19 Wesseling-Perry K, "Chronic kidney disease: mineral and bone disorder in children" 33 : 169-179, 2013

20 Wesseling-Perry K, "Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism" 79 : 112-119, 2011